ATTENSI
9.12.2021 08:02:09 CET | Business Wire | Press release
SAP SuccessFactors is the leading human capital management (HCM) solution, helping customers stay ahead of the competition to attract, develop and retain the best employees and ensuring a holistic employee journey throughout the employee lifecycle. Attensi delivers groundbreaking gamification and simulation-based training. Through this collaboration, the partners will offer an innovative learning experience using, among other approaches, gaming technology and competitive elements. The collaboration means that the two platforms work together to ensure a unified user experience and natural data flow, with the allocation and follow-up of learning as well as competence and development.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211208006137/en/
“We are currently in an era of change and rapid technological development where learning and competence development are becoming increasingly more important to businesses. It is incredibly rewarding to be able to embrace successful HR tech "scale-ups" such as Attensi, so that we can offer innovative technology like this as part of our open ecosystem to the benefit of our rapidly growing customer community."
– Jens Conradi, Sales Director, SAP SuccessFactors
The solutions that Attensi offers combines advanced 3D simulation with deep insight into human behavior and psychology. Employees encounter virtual scenarios that are individually adapted to the individual business and bring to life actual experiences from the organization's reality. As employees evolve, they get educational, personalized feedback, and scores on their results. In addition, Attensi allows you to engage employees with automated campaigns and communication. As a manager, you can easily follow your team in real time, provide feedback to your employees, and measure the impact of the learning.
"The collaboration with SAP SuccessFactors is of strategic importance to Attensi. We can now offer customers who use SuccessFactors a seamless learning experience where the best elements of SuccessFactors play together with Attensi's solutions and platform. This enables even better and faster competence development and behavioral training for all the millions of employees in the companies that use SuccessFactors."
– Trond Aas, CEO, Attensi
"This is a major milestone in the development of the Attensi Technology Platform! Having achieved all qualifications required by SAP to enter a partnership recognizes Attensi as a top player in the field. We are extremely excited to provide our users access to world-leading learning technology delivered seamlessly in SAP SuccessFactor's global platform."
– Anne Lise Waal, CTO & COO, Attensi
About Attensi
Attensi delivers next generation simulation-based learning technology based on game mechanics and behavioral psychology that impacts KPIs and drives change in large organizations. Attensi is headquartered in Oslo, Norway, with offices in UK, USA and Germany and has delivered over 500 simulation solutions in over 20 languages to a global user base.
About SAP SuccessFactors
SAP's solutions help more than 400,000 customers around the world work better together using business insights more efficiently. Originally known for ERP software, SAP has evolved to become the market leader in business applications and related services for data, analytics, and intelligent technologies.
SAP SuccessFactors is a cloud-based, holistic HR solution that supports the entire employee journey including recruitment, onboarding, talent development, payroll, and HR analytics. SAP SuccessFactors provides personalized user experiences that facilitate competence development and more engaged and productive employees. SAP SuccessFactors has 200 million users in over 7,000 businesses worldwide, of which over 40 Norway. The solution is located in 101 countries and supports 43 languages.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211208006137/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Acceleronix, IDEMIA Secure Transactions and Orange Announce Flexible, Single-SKU Manufacturing with Quantum-Safe IFPP4.11.2026 16:44:00 CET | Press release
One SKU. Every market. Connectivity decided at the end of production. Live at electronica 2026. Orange, one of the world’s leading telecom operators, has joined the global quantum-safe In-Factory Profile Provisioning (IFPP) program, jointly launched by Acceleronix and IDEMIA Secure Transactions at MWC Barcelona in February. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104070181/en/ Acceleronix, IDEMIA Secure Transactions and Orange announce flexible, single-SKU manufacturing with quantum-safe IFPP The program enables device makers to build a single product for every market and connect it to the Orange network before it leaves the factory. Acceleronix and IDEMIA Secure Transactions will demonstrate the solution live at electronica 2026, the international electronics trade fair, at Messe München, Hall C2, Stand 601, from 10 to 13 November. Most connected devices share the same weak spot: provisioning and testing on the pr
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release
If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release
This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 15:00:00 CET | Press release
New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compoundsUpdated results for INCA033989 in second-line MF and second-line essential thrombocythemia (ET) will build on previously presented datasetsLong-term Phase 1/2 data further characterize the potential of latarcibart (VGA039), an investigational Protein S-targeting antibody, as prophylaxis in adolescents and adults with von Willebrand disease (VWD)More than 30 abstracts will highlight progress across Incyte’s broader hematology portfolioIncyte will host an investor event and webcast on Saturday, December 12, 2026 from 7:30 – 9:00 p.m. CT (8:30 – 10:00 p.m. ET) Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstra
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 15:00:00 CET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom